Open AccessPlacental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia
Author(s) -
Berthold Huppertz,
Hamutal Meiri,
Sveinbjörn Gizurarson,
George Osol,
Marei Sammar
Publication year - 2013
Publication title -
human reproduction update
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.977
H-Index - 180
eISSN - 1362-4946
pISSN - 1355-4786
DOI - 10.1093/humupd/dmt003
Subject(s) - eclampsia , drug , medicine , obstetrics , pregnancy , pharmacology , bioinformatics , intensive care medicine , biology , genetics
Pre-eclampsia affects 2-7% of all pregnant women and is a major cause of maternal and fetal morbidity and mortality. The etiology of pre-eclampsia is still unknown but it is well documented that impaired placentation is a major contributor to its development. One of the placenta-specific proteins is placental protein 13 (PP13). Lower first trimester levels of maternal serum PP13 and its encoding placental mRNA are associated with the development of both early and late-onset severe pre-eclampsia. In cases where this protein is mutated, the frequency of pre-eclampsia is higher.